【24h】

Conventional Phenylketonuria Treatment

机译:常规苯丙酮尿症治疗

获取原文
获取外文期刊封面目录资料

摘要

Phenylketonuria (PKU) is caused by a deficient activity of enzyme phenylalanine (Phe) hydroxylase, which results in high Phe blood concentration, which is toxic to the central nervous system. The fundamental purpose of nutritional treatment is to reduce and maintain blood Phe between 2 mg/dL (120 ???μmol/L) and 6 mg/dL (360 ???μmol/L) in order to prevent neuropathogenic complications. At the same time, nutrition support must provide enough energy and nutrients to promote normal growth and development and also to avoid vitamin and mineral deficiencies. Phenylketonuria treatment must be maintained long-life and its adherence must be frequently assessed. The amount of Phe required by patients with PKU varies throughout life and must be adjusted according to individual tolerance, residual phenylalanine hydroxylase enzymatic activity, age, sex, growth rate, protein intake, and nutritional and biochemical status among others. Treatment must be done by trained personnel. It is necessary to unify treatment criteria and further research must be done.
机译:苯丙酮尿症(PKU)由苯丙氨酸(Phe)羟化酶活性不足引起,导致高Phe血药浓度,对中枢神经系统有毒。营养治疗的基本目的是将血液Phe降低并维持在2 mg / dL(120μmol/ L)和6 mg / dL(360μmol/ L)之间,以预防神经病性并发症。同时,营养支持必须提供足够的能量和营养,以促进正常的生长和发育,并避免维生素和矿物质的缺乏。苯丙酮尿症治疗必须保持长寿命,并且必须经常评估其依从性。 PKU患者所需的Phe量在整个生命中都不同,必须根据个人耐受性,残留的苯丙氨酸羟化酶活性,年龄,性别,生长速度,蛋白质摄入以及营养和生化状况等进行调整。必须由经过培训的人员进行治疗。有必要统一治疗标准,并且必须做进一步的研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号